RT Journal Article
SR Electronic
T1 Towards a phenome-wide view of Parkinson’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.01.22270276
DO 10.1101/2022.02.01.22270276
A1 Abby L. Olsen
A1 Joseph J. Locascio
A1 Idil Tuncali
A1 Nada Laroussi
A1 Elena Abatzis
A1 Polina Kamenskaya
A1 Yuliya Kuras
A1 Tom Yi
A1 Aleksandar Videnovic
A1 Michael T. Hayes
A1 Gary P. H. Ho
A1 Jordan Paulson
A1 Vikram Khurana
A1 Todd M. Herrington
A1 Bradley T. Hyman
A1 Dennis J. Selkoe
A1 John H. Growdon
A1 Stephen N. Gomperts
A1 Trond Riise
A1 Michael A. Schwarzschild
A1 Albert Y. Hung
A1 Anne-Marie Wills
A1 Clemens R. Scherzer
YR 2022
UL http://medrxiv.org/content/early/2022/02/02/2022.02.01.22270276.abstract
AB Background and Objectives Many studies have examined the relation between PD and environmental variables serially --- one candidate association at a time. In the real world however, both environmental exposures and patients are much more complex, including correlated environmental exposures, polypharmacy, and complex comorbidities. Here we begin to characterize a holistic view of environmental, health, and pharmacological traits linked to patients with PD.Methods The Harvard Biomarkers Study (HBS) is a large case-control study of PD patients and healthy controls that includes an extensive questionnaire covering past medical and social history data and is thus well-suited for such an exploratory study. Sixty-four environmental, pharmacological, and clinical features were evaluated for associations with PD using logistic regression analysis with backward elimination.Results Male gender, coronary artery disease, depression, anxiety, restless leg syndrome, head trauma, ibuprofen use, co-enzyme Q10 use, and vitamin D supplementation were significantly positively associated with PD. By contrast, asthma/chronic obstructive pulmonary disease (COPD), naproxen, ezetimibe, and smoking were significantly negatively associated with PD.Discussion This study shows that unbiased, data-rich exploration of the Parkinson phenome has the promise to uncover, prioritize, and clarify associations between environment, multi-system health phenotypes, and PD in a patient-centric manner. Associations with coronary artery disease, mood disorders, and the cholesterol-absorption inhibitor ezetimibe were revealed that have been largely neglected in traditional hypothesis-driven investigations. Interestingly, asthma/COPD was inversely associated with PD, and this was independent of smoking history. Furthermore, well-established associations were confirmed for male gender, smoking, head trauma, and restless legs syndrome.Competing Interest StatementC.R. Scherzer is named as co-inventor on a US patent application on sphingolipids biomarkers that is jointly held by Brigham & Womens Hospital and Sanofi. CRS has consulted for Sanofi Inc. and Calico; has collaborated with Pfizer, Opko, and Proteome Sciences, Genzyme Inc., and Lysosomal Therapies; is on the Scientific Advisory Board of the American Parkinson Disease Association; has served as Advisor to the Michael J. Fox Foundation, NIH, Department of Defense, and Google; has received funding from the NIH, the U.S. Department of Defense, the Michael J. Fox Foundation, and the American Parkinson Disease Association. A-M. Wills reports research funding from the Parkinsons Foundation, has participated in clinical trials funded by Sanofi/Genzyme, Roche, Transposon therapeutics and received consultant payments from Accordant, CVS/Caremark, and Sanofi/Genzyme. A.L. Olsen, J.J. Locascio, I. Tuncali, N. Laroussi, E. Abatzis, P. Kamenskaya, Y. Kuras, T. Yi, A. Videnovic, M.T. Hayes, G.P.H. Ho, J. Paulson, V. Khurana, T.M. Herrington, B.T. Hyman, D.J. Selkoe, J.H. Growdon, S.N. Gomperts, T. Riise, M.A. Schwarzschild, and A.Y. Hung report no disclosures relevant to the manuscript.Funding StatementHBS was seeded by generous support from the Harvard NeuroDiscovery Center, with partial contributions from APDA, the Michael J Fox Foundation, NINDS U01NS082157, U01NS100603, and the Massachusetts Alzheimers Disease Research Center NIA P50AG005134. C.R.S.'s work is supported by NIH grants U01NS095736, U01NS100603, R01AG057331, and R01NS115144, and the American Parkinson Disease Association Center for Advanced Parkinson Research. The study is funded by the joint efforts of The Michael J. Fox Foundation for Parkinsons Research (MJFF) and the Aligning Science Across Parkinsons (ASAP) initiative. MJFF administers the grant [ASAP-000301] on behalf of ASAP and itself. A.L.O.'s work was funded by NINDS K08NS109344-0, the American Parkinsons Disease Association George C. Cotzias Memorial Fellowship, and DoD W81XWH-18-1-0395Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of Mass General Brigham gave ethical approval of this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsPDParkinson’s diseaseHBSHarvard Biomarkers Study